Anti-immunoglobulin E (omalizumab) therapy in allergic asthma.

Several large-scale, double-blind, randomized, placebo-controlled clinical trials of the anti-immunoglobulin E (IgE) monoclonal antibody, rhuMAb-E25 (omalizumab) have demonstrated the benefits of this agent in patients with moderate to severe allergic asthma who remain symptomatic despite treatment with systemic or inhaled corticosteroids. The trials have consistently shown that administration of omalizumab is associated with fewer asthma exacerbations per patient despite significant reductions in corticosteroid dose, stable symptom control despite concomitant reductions in rescue medication use, and improvement in quality of life compared with placebo. In addition, anti-IgE (omalizumab) has been shown to be safe and well tolerated.

[1]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[2]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[3]  S. Szefler.  Challenges in assessing outcomes for pediatric asthma. , 2001, The Journal of allergy and clinical immunology.

[4]  Salvi Ss,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. , 1999 .

[5]  R. Bush,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. , 1999, The New England journal of medicine.

[6]  L. Boulet,et al.  Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. , 1999, American journal of respiratory and critical care medicine.

[7]  R. Dockhorn,et al.  Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[8]  L. Boulet,et al.  Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. , 1997, American journal of respiratory and critical care medicine.

[9]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[10]  D. Blainey,et al.  The cost of acute asthma--how much is preventable? , 1990, Health trends.